Man Group PLC Y M Abs Therapeutics, Inc. Transaction History

Man Group PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$4.86 - $7.23 $32,139 - $47,811	6,613 Added 42.82%	22,057 $120,000
Q2 2023 Aug 14, 2023	SELL	$5.68 - $10.34 $260,263 - $473,789	-45,821 Reduced 74.79%	15,444 $104,000
Q1 2023 May 15, 2023	BUY	$2.83 - $5.11 $93,169 - $168,231	32,922 Added 116.16%	61,265 $306,000
Q4 2022 Feb 14, 2023	BUY	$3.0 - $15.17 $54,129 - $273,712	18,043 Added 175.17%	28,343 $138,000
Q3 2022 Nov 14, 2022	BUY	$13.96 - $19.67 $143,788 - $202,601	10,300 New	10,300 $149,000
Q4 2018 Feb 14, 2019	SELL	$15.41 - $28.92 $616,400 - $1.16 Million	-40,000 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$24.0 - $26.97 $960,000 - $1.08 Million	40,000 New	40,000 $1.06 Million

106

24.5M

40.3K

400

Ticker YMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,719,500
Market Cap $356M
Description
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.